Application of Biomarkers in Neurological Diseases

Biomarkers Clinical Trial

Official title:

Application of Biomarkers in Neurological Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05881226
• Other study ID #: Bio-Neuro
• Status: Recruiting
• Start date: June 5, 2023
• Est. completion date: December 1, 2031

Study information

• Verified date: February 2024
• Source: The First Hospital of Jilin University
• Contact: Yi YY Yang, Ph.D.
• Phone: 18186872986
• Email: doctoryangyi[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To explore the predictive and diagnostic role of biomarkers in patients with neurological diseases.

Description:

With the rise and continuous development of omics technology and bioinformatics technology, some scholars have applied proteomics technology and metabolomics technology to study the brain tissue, plasma and CSF of patients with nervous system diseases, so as to screen out potential biomarkers, with a view to providing new research ideas for pathogenesis and early diagnosis of neurological diseases. At present, the research on some novel biomarkers is still in its infancy, and many key problems remain to be solved. It is necessary to further determine the expression level of biomarkers in normal human body and the characteristics of biomarkers in patients with neurological diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 1, 2031
• Est. primary completion date: December 1, 2030
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients with neurological diseases;

2. Subjects or legal agents agree to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Participating in other clinical investigators;

2. Unwilling to be followed up or poor treatment compliance;

3. Other conditions considered unsuitable for inclusion by the researchers.

Related Conditions & MeSH terms

• Biomarkers
• Nervous System Diseases

Locations

Country	Name	City	State
China	First Hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Yi Yang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mRS score in 90 days	The proportion of 3-month good functional outcome (mRS Score 0-2) in patients with neurological diseases was evaluated by mRS Score	3 months